Exenatide
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
AstraZeneca · Phase 3 · Terminated · Enrollment 13
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Dapagliflozin plus Exenatide | Obesity + T2D | n/r | n/r | n/r | n/r |
| Placebo plus Placebo | Obesity + T2D | n/r | n/r | n/r | n/r |
| Placebo plus Exenatide | Obesity + T2D | n/r | n/r | n/r | n/r |